Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Septo-optic dysplasia with associated closed lip schizencephaly: "SOD-plus syndrome".
Acta Neurol Belg
January 2025
Department of Ophthalmology and Vision Sciences, University of Toronto, 2075 Bayview Ave, North York, ON, M4N 3M5, Canada.
Structural and luminescent properties of a Cr/Sm doped GdAlO orthorhombic perovskite for solid-state lighting applications.
RSC Adv
January 2025
Departamento de Física Aplicada, Facultade de Óptica e Optometríae Instituto de Materiais (iMATUS) Campus Vida, Universidade de Santiago de Compostela (USC) 15782 Galicia Spain.
The Cr and Sm doped GdAlO perovskite with formula GdSmAlCrO, was synthesized a solid-state reaction method, and its structure, morphology, and photoluminescence properties were thoroughly investigated. The compound crystallizes in the orthorhombic space group, with Cr transition-metal ions substituting Al in the octahedral symmetry site, and Sm lanthanide (rare-earth) ions occupying the tetrahedral site. The material's morphology and chemical composition homogeneity were evaluated through Scanning Electron Microscopy (SEM) and Energy Dispersive X-ray analysis.
View Article and Find Full Text PDFExtracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes.
Biomark Res
January 2025
Laboratory of Cellular Therapy, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena, Modena, 41124, Italy.
Emerging evidence highlights the key role of microRNA (miR)-21 in cell-to-cell communication and tumorigenesis. However, limited knowledge exists on the levels and clinical meaning of miR-21 in extracellular vesicles (EVs) of patients with breast cancer (BC). We assessed EV-derived miR-21 levels in one hundred women: 30 with early BC (EBC), 30 with metastatic BC on treatment progression (MBC), 30 cancer survivors on follow-up (FU) and 10 healthy donors (HD) as age- and body mass index (BMI)-matched controls.
View Article and Find Full Text PDFReal-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma.
Biomark Res
January 2025
Incyte Corporation, Wilmington, DE, USA.
Potential CD19 antigen loss following CD19-directed therapy has raised concerns over sequential use of these therapies. Tafasitamab, a CD19-targeting immunotherapy, combined with lenalidomide, is approved for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) treatment in adults ineligible for autologous stem cell transplantation. This retrospective analysis examined characteristics and outcomes of adults with R/R DLBCL who received tafasitamab preceding CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy in a real-world setting.
View Article and Find Full Text PDFAberrant c-AMP signalling in richter syndrome revealed by single-cell transcriptome and 3D chromatin analysis.
Biomark Res
January 2025
Department of Hematology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Richter syndrome (RS), characterized by aggressive lymphoma arising from chronic lymphocytic leukaemia (CLL), presents a poor response to treatment and grim prognosis. To elucidate RS mechanisms, paired samples from a patient with DLBCL-RS were subjected to single-cell RNA sequencing (scRNA-seq) and high-throughput chromosome conformation capture (Hi-C) sequencing. Over 10,000 cells were profiled via scRNA-seq, revealing the comprehensive B cell transformation in RS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!